<- Go Home
Starling Oncology, Inc.
Starling Oncology, Inc., an oncology company, provides various oncology services in the United States. It operates through three segments: Specialty pharmacy, Patient Services, and Clinical Trials & Other. The company offers physician services, in-house infusion, in-house specialty pharmacy, clinical trials, radiation therapy, and outpatient blood product transfusion services, as well as educational seminars, support groups, counseling services, and 24/7 patient assistance and support services. It also manages clinical trials and palliative care programs; operates combined community clinics and infusion suites; and operates a specialty pharmacy that includes both in-office and mail-order dispensing for complementary oral and self-injectable medications taken by patients concurrent with their in-office cancer therapies. It serves adult and senior cancer patients. The company was formerly known as The Oncology Institute, Inc. and changed its name to Starling Oncology, Inc. in August 2026. Starling Oncology, Inc. was founded in 2007 and is headquartered in Cerritos, California.
Market Cap
$638.0M
Volume
2.0M
Cash and Equivalents
$41.1M
EBITDA
-$19.3M
Tax Rate Collected
N/A
Tax Rate Ratio
N/A
Gross Profit
$92.2M
Profit Margin
15.69%
52 Week High
$7.05
52 Week Low
$2.32
Dividend
N/A
Price / Book Value
-25.24
Price / Earnings
-20.58
Price / Tangible Book Value
-15.07
Enterprise Value
$701.7M
Enterprise Value / EBITDA
-77.56
Operating Income
-$26.1M
Return on Equity
214.12%
Return on Assets
-9.65
Cash and Short Term Investments
$41.1M
Debt
$104.8M
Equity
-$24.9M
Revenue
$587.2M
Unlevered FCF
$8.5M
Sector
Health Care Providers and Services
Category
N/A